Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA2 | P51531 | 2/20 | 0.40 |
| ▸ | SMARCA4 | P51532 | 2/20 | 0.40 |
| ▸ | PBRM1 | Q86U86 | 2/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16826747 | 1.00 | SMARCA2 (0.40) | SMARCA2SMARCA4PBRM1NR1H2PTPN11 | |
| SCHEMBL16854543 | 0.82 | SCN9A (0.56) | SMARCA2SMARCA4PBRM1PTPN11 | |
| SCHEMBL18578924 | 0.82 | SCN9A (0.56) | SMARCA2SMARCA4PBRM1PTPN11 | |
| SCHEMBL16854617 | 0.79 | SCN9A (0.42) | NR1H2GPR119MAP4K4SRC | |
| SCHEMBL16854530 | 0.79 | SCN9A (0.42) | NR1H2GPR119MAP4K4SRC | |
| SCHEMBL16826888 | 0.79 | SCN9A (0.42) | NR1H2GPR119MAP4K4SRC | |
| SCHEMBL24239610 | 0.79 | SMARCA2 (0.41) | SMARCA2SMARCA4PBRM1NR1H2GPR119 | |
| SCHEMBL31681461 | 0.79 | SMARCA2 (0.41) | SMARCA2SMARCA4PBRM1NR1H2GPR119 | |
| SCHEMBL29373357 | 0.79 | SMARCA2 (0.41) | SMARCA2SMARCA4PBRM1NR1H2GPR119 | |
| SCHEMBL23580619 | 0.79 | SMARCA2 (0.41) | SMARCA2SMARCA4PBRM1NR1H2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10844076-B2 | Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine | NEKTAR THERAPEUTICS (US) | 2020-11-24 | — | — | US | disclosed |
| US-20190071454-A1 | DERIVATIVES OF 6-(2,3-DICHLOROPHENYL)-1,2,4-TRIAZIN-5-AMINE | NEKTAR THERAPEUTICS | 2019-03-07 | — | — | US | disclosed |
| US-10189859-B2 | Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine | NEKTAR THERAPEUTICS (US) | 2019-01-29 | — | — | US | disclosed |
| US-20170066782-A1 | DERIVATIVES OF 6-(2,3-DICHLOROPHENYL)-1,2,4-TRIAZIN-5-AMINE | NEKTAR THERAPEUTICS | 2017-03-09 | — | — | US | disclosed |
| WO-2015092819-A2 | DERIVATIVES OF 6-(2,3-DICHLOROPHENYL)-1,2,4-TRIAZIN-5- AMINE | NEKTAR THERAPEUTICS (INDIA) PVT. LTD. (IN) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10844076-B2 | Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine | KCNJ2, TRPC5, RYR2 | SMARCA2 3438/4885SMARCA4 3204/4885PBRM1 2268/4885 |
| US-20190071454-A1 | DERIVATIVES OF 6-(2,3-DICHLOROPHENYL)-1,2,4-TRIAZIN-5-AMINE | KCNJ2, TRPC5, RYR2 | SMARCA2 3438/4885SMARCA4 3204/4885PBRM1 2268/4885 |
| US-20170066782-A1 | DERIVATIVES OF 6-(2,3-DICHLOROPHENYL)-1,2,4-TRIAZIN-5-AMINE | KCNJ2, TRPC5, RYR2 | SMARCA2 3438/4885SMARCA4 3204/4885PBRM1 2268/4885 |
| US-10189859-B2 | Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine | KCNJ2, TRPC5, RYR2 | SMARCA2 3438/4885SMARCA4 3204/4885PBRM1 2268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.